SCHEMBL2209540

SCHEMBL2209540

CS(=O)(=O)c1nc(-c2cccc(-c3ccccc3)c2)cc2ccnn12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.36
NTRK1 P04629 1/20 0.36
MET P08581 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR1 P11362 1/20 0.36
MAP2K2 P36507 1/20 0.36
FLT3 P36888 1/20 0.36
MAPK8 P45983 1/20 0.36
GSK3B P49841 1/20 0.36
NTRK3 Q16288 1/20 0.36
ALK Q9UM73 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
SDHB P21912 3/20 0.36
LMNA P02545 3/20 0.36
HPGD P15428 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
HTT P42858 2/20 0.36
KMT2A Q03164 2/20 0.36
TLR9 Q9NR96 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2214081 0.92 SCD (0.42) BPTFNTRK1METPIM1FGFR1
SCHEMBL2213858 0.86 CDK2 (0.42) HPGDNPSR1KMT2AMEN1TP53
SCHEMBL2211402 0.84 BPTF (0.37) BPTFNTRK1METPIM1FGFR1
SCHEMBL2214323 0.83 ALDH1A1 (0.41) LMNAHPGDNPSR1HTTKMT2A
SCHEMBL2882567 0.83 RAD52 (0.47) KMT2AMEN1TP53POLBSTAT1
SCHEMBL2211383 0.82 CYP2C9 (0.45) RAB9AALDH1A1CYP2C9TDP1CYP1A2
SCHEMBL2882272 0.80 FYN (0.48) HPGDNPSR1KMT2AMEN1TP53
SCHEMBL2876715 0.79 PLCG1 (0.43) LMNAHPGDNPSR1KMT2AMEN1
SCHEMBL2214072 0.77 FYN (0.50) HPGDHTTKMT2AMEN1TP53
SCHEMBL2215071 0.77 ALOX5 (0.42) HPGDKMT2AMEN1RAB9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 BPTF 1476/4885NTRK1 2272/4885MET 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.